International Journal of Biomedicine (Mar 2017)
Experimental Testing of the New Biomedical Substance of Pig Kidneys for the Treatment of Nephrolithiasis
Abstract
The aim of our study was to test anti-lithogenic activity of the new biomedical substance from pig kidneys (PK-BMS) on the experimentally induced nephrolithiasis. Materials and Methods: The experiments were performed with 30 male Wistar outbred rats weighting 220g-280g. The experimental animals were divided into two groups. In the disease-control group (DCG), the animals received a 1% solution of EG for 6 weeks. The rats in therapy group (TG), beginning from the fourth week, in addition to the daily EG intake, received PK-BMS in the amount of 1.0 per rat. The production of this substance was carried out at Altaivitaminy ZAO (Biysk, Altai Krai, Russia) by the method of cool dehumidification. In daily urine, we determined the concentration of oxalate, phosphate and calcium ions, creatinine excretion every 3 or 4 days in both groups; the activity of LDH, GGT, and NAG was measured every 7 days in the injured kidney epithelium. For the study of free-radical oxidation activity and for morphological examination of animal kidneys, after 6 weeks of the experiment, 5 rats from each group were euthanized. The occurrence of calcium compounds was determined by von Kossa’s staining method. Results: After a 6-week EG intake, we found the typical biochemical and morphological symptoms of experimental nephrolithiasis in rats of DCG: urine supersaturation with oxalate ions, significant increase in the activity of marker enzymes, activation of free-radical oxidation in the kidneys, and formation of calcium deposits in the kidneys. In TG, the new PK-BMS intake resulted in a significant alleviation of the experimental nephrolithiasi: significant decrease in the level of oxalate ions and activity of marker enzymes, reduction of free-radical oxidation in the kidneys, decrease in the number and size of calcium deposits in the area of renal papillae. Conclusion: It was established that during the experimental nephrolithiasis, a three-week intake of the new PK-BMS is accompanied by a significant anti-lithogenic effect.
Keywords